Whitehawk Therapeutics (WHWK) Non-Current Debt (2021)
Whitehawk Therapeutics (WHWK) posted quarterly Non-Current Debt of $5.8 million for Q4 2021, little changed quarter-over-quarter from $5.8 million in Q3 2021.
Whitehawk Therapeutics (WHWK) Non-Current Debt (2021) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported Non-Current Debt for 1 consecutive years, with $5.8 million the latest figure, recorded in Q4 2021.
- In Q4 2021, Non-Current Debt changed N/A year-over-year to $5.8 million; the TTM figure through Dec 2021 stood at $5.8 million (changed N/A YoY), while the FY2021 annual figure was $5.8 million, changed N/A from the prior year.
- Non-Current Debt held at $5.8 million in Q4 2021 per WHWK's latest filing, from $5.8 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $5.8 million in Q3 2021 and bottomed at $5.8 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Whitehawk Therapeutics | 369.67 Mn | 74.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 5.76 Mn |
| Sep 30, 2021 | 5.76 Mn |